SIGA Technologies, Inc.

83 articles about SIGA Technologies, Inc.

• SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

  11/7/2023

  SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three and nine months ended September 30, 2023.

• SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results

  10/26/2023

  SIGA Technologies, Inc. today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023.

• SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

  10/23/2023

  SIGA Technologies, Inc. announced the creation by the European Commission’s DG HERA of a joint procurement mechanism under which 13 participating countries from the European Union and the European Free Trade Association can efficiently order oral TPOXX.

• SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

  9/6/2023

  SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer.

• SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023

  8/8/2023

  SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three and six months ended June 30, 2023.

• SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results

  7/27/2023

  SIGA Technologies, Inc. today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 8th, 2023.

• SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

  7/27/2023

  SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113 million worth of oral TPOXX® treatment courses and approximately $25 million worth of IV TPOXX® treatment courses.

• SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium

  6/27/2023

  SIGA Technologies, Inc. announced that SIGA CEO Phil Gomez, PhD, will present an overview of the role of therapeutics in global planning and response to potential outbreaks of smallpox and other orthopox viruses during the upcoming NATO Chemical, Biological, Radiological & Nuclear Medical Symposium in Oak Ridge, Tennessee.

• SIGA Reports Financial Results for Three Months Ended March 31, 2023

  5/4/2023

  SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three months ended March 31, 2023.

• SIGA Declares Special Cash Dividend of $0.45 Per Share

  5/4/2023

  SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that the Board of Directors declared a special cash dividend of $0.45 per share on the common stock of the Company.

• SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results

  4/27/2023

  SIGA Technologies, Inc. today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 4th, 2023.

• SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022

  3/2/2023

  SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three and twelve months ended December 31, 2022.

• SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results

  2/23/2023

  SIGA Technologies, Inc. today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 2nd, 2023.

• SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023SIGA Board of Directors has initiated search for new CEO

  1/17/2023

  SIGA Technologies, Inc. today announced that Phil Gomez, PhD, Chief Executive Officer of SIGA, has announced his intention to retire as CEO in 2023.

• SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022

  11/3/2022

  SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three and nine months ended September 30, 2022.

• SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results

  10/27/2022

  SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 3rd, 2022.

• SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

  10/12/2022

  SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox.

• SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®- In 2022

  9/29/2022

  SIGA Technologies, Inc. today announced that the U.S. Department of Defense (DoD) awarded a new contract to SIGA for the procurement of up to $10.7 million of oral TPOXX.

• SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)

  9/26/2022

  SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced receipt of approximately $16 million of international procurement orders for oral TPOXX®.

• SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®

  8/9/2022

  SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of procurement options under its 75A50118C00019 (19C) contract with the U.S. Department of Health and Human Services for the delivery to the U.S. government of intravenous (IV) formulation of TPOXX treatment courses valued at approximately $26 million.